SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-027623
Filing Date
2021-05-13
Accepted
2021-05-13 16:58:42
Documents
61
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ovid-10q_20210331.htm 10-Q 1979924
2 EX-10.1 ovid-ex101_428.htm EX-10.1 495022
3 EX-31.1 ovid-ex311_9.htm EX-31.1 23589
4 EX-31.2 ovid-ex312_6.htm EX-31.2 23895
5 EX-32.1 ovid-ex321_8.htm EX-32.1 8565
6 GRAPHIC gvedip405tty000001.jpg GRAPHIC 86179
  Complete submission text file 0001564590-21-027623.txt   6526929

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT ovid-20210331.xml EX-101.INS 997346
8 XBRL TAXONOMY EXTENSION SCHEMA ovid-20210331.xsd EX-101.SCH 44130
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ovid-20210331_cal.xml EX-101.CAL 39896
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ovid-20210331_def.xml EX-101.DEF 171116
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE ovid-20210331_lab.xml EX-101.LAB 362840
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ovid-20210331_pre.xml EX-101.PRE 281474
Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38085 | Film No.: 21920535
SIC: 2834 Pharmaceutical Preparations